These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

213 related items for PubMed ID: 25544610

  • 1. Peters plus syndrome mutations disrupt a noncanonical ER quality-control mechanism.
    Vasudevan D, Takeuchi H, Johar SS, Majerus E, Haltiwanger RS.
    Curr Biol; 2015 Feb 02; 25(3):286-295. PubMed ID: 25544610
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Peters plus syndrome mutations affect the function and stability of human β1,3-glucosyltransferase.
    Zhang A, Venkat A, Taujale R, Mull JL, Ito A, Kannan N, Haltiwanger RS.
    J Biol Chem; 2021 Jul 02; 297(1):100843. PubMed ID: 34058199
    [Abstract] [Full Text] [Related]

  • 5. O-fucosylation stabilizes the TSR3 motif in thrombospondin-1 by interacting with nearby amino acids and protecting a disulfide bond.
    Berardinelli SJ, Eletsky A, Valero-González J, Ito A, Manjunath R, Hurtado-Guerrero R, Prestegard JH, Woods RJ, Haltiwanger RS.
    J Biol Chem; 2022 Jun 02; 298(6):102047. PubMed ID: 35597280
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. High-Throughput miRFluR Platform Identifies miRNA Regulating B3GLCT That Predict Peters' Plus Syndrome Phenotype, Supporting the miRNA Proxy Hypothesis.
    Thu CT, Chung JY, Dhawan D, Vaiana CA, Mahal LK.
    ACS Chem Biol; 2021 Oct 15; 16(10):1900-1907. PubMed ID: 34085516
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Contribution of a Novel B3GLCT Variant to Peters Plus Syndrome Discovered by a Combination of Next-Generation Sequencing and Automated Text Mining.
    Totoń-Żurańska J, Kapusta P, Rybak-Krzyszkowska M, Lorenc K, Machlowska J, Skalniak A, Filipek E, Pawlik D, Wołkow PP.
    Int J Mol Sci; 2019 Nov 28; 20(23):. PubMed ID: 31795264
    [Abstract] [Full Text] [Related]

  • 10. O-Fucosylation of ADAMTSL2 is required for secretion and is impacted by geleophysic dysplasia-causing mutations.
    Zhang A, Berardinelli SJ, Leonhard-Melief C, Vasudevan D, Liu TW, Taibi A, Giannone S, Apte SS, Holdener BC, Haltiwanger RS.
    J Biol Chem; 2020 Nov 13; 295(46):15742-15753. PubMed ID: 32913123
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Two distinct pathways for O-fucosylation of epidermal growth factor-like or thrombospondin type 1 repeats.
    Luo Y, Nita-Lazar A, Haltiwanger RS.
    J Biol Chem; 2006 Apr 07; 281(14):9385-92. PubMed ID: 16464858
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. O-Glycosylation modulates the stability of epidermal growth factor-like repeats and thereby regulates Notch trafficking.
    Takeuchi H, Yu H, Hao H, Takeuchi M, Ito A, Li H, Haltiwanger RS.
    J Biol Chem; 2017 Sep 22; 292(38):15964-15973. PubMed ID: 28729422
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.